Lung Cancer | Specialty

Dr. Liu on ALK-Targeted Agents in NSCLC

July 3rd 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses ALK-targeted agents in the field of non–small cell lung cancer (NSCLC).

Dr. Langer on the IMpower150 Trial in NSCLC

July 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

FDA Grants Frontline Pembrolizumab Regimen Priority Review for Squamous NSCLC

July 2nd 2018

The FDA has granted a priority review designation to a supplemental biologics license application for first-line pembrolizumab for use in combination with carboplatin/paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer, regardless of PD-L1 expression.

Team Spirit Guides Gandara in Personalizing Care

June 30th 2018

David R. Gandara, MD, has pioneered groundbreaking therapies in lung cancer treatment through his leadership of interdisciplinary teams of oncologists, pharmacologists, molecular biologists, and statisticians.

Dr. Villaruz Discusses PD-L1 Expression in Lung Cancer

June 29th 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC

June 29th 2018

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses the updated efficacy and safety data from the global phase III ALEX study of alectinib (Alecensa) versus crizotinib (Xalkori) in untreated advanced ALK-positive non–small cell lung cancer (NSCLC).

Bazhenova Highlights Treatments for ALK+ NSCLC, Less Common Drivers

June 29th 2018

Lyudmila A. Bazhenova, MD, discusses treatments for patients with ALK-positive NSCLC, as well as the progress in less common oncogenic drivers, such as NTRK fusions.

Expert Elaborates on Developments in SCLC and EGFR-Mutant NSCLC

June 28th 2018

Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.

Dr. Garon Discusses Pegilodecakin Plus a PD-1 Inhibitor in NSCLC

June 28th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the combination of pegilodecakin (AM0010) and a PD-1 inhibitor in patients with advanced non–small cell lung cancer.

Emerging Treatment Regimens in Advanced NSCLC

June 28th 2018

Immuno-Oncology in NSCLC: Cost Versus Benefit

June 28th 2018

Advanced Squamous NSCLC: The IMpower131 Study

June 28th 2018

Adjuvant Versus Neoadjuvant Therapy in NSCLC

June 28th 2018

Neoadjuvant Nivolumab in NSCLC

June 28th 2018

Implications for Using Durvalumab in Stage 3 NSCLC

June 28th 2018

The PACIFIC Trial in Stage 3 NSCLC

June 28th 2018

Concurrent Chemoradiotherapy in Stage III NSCLC

June 28th 2018

Baseline Steroid Use in NSCLC

June 28th 2018

First-Line Therapy in PD-L1 Advanced NSCLC

June 28th 2018

Interpreting the Results of CheckMate-227 in NSCLC

June 28th 2018